Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research[1].
Samalizumab 被合理设计为具有 Ig G2/G4 恒定区，以最大限度地减少效应子功能并保护免疫细胞亚群。Samalizumab 是一种重组人源化抗 CD200 单抗，旨在消除效应子功能，特异性结合免疫检查点 CD200，阻断受体参与和信号传导，并拮抗 CD200 驱动的免疫抑制，从而发挥抗肿瘤作用免疫反应[1]。
[1]. Daruka Mahadevan, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019 Aug 23;7(1):227.